Overview

To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Hepatic Function and Hepatic Impairment.

Status:
Recruiting
Trial end date:
2021-12-29
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the pharmacokinetics and safety of parsaclisib in participants With normal hepatic function and participants with hepatic impairment.
Phase:
Phase 1
Details
Lead Sponsor:
Incyte Corporation